机构:[1]Beijing Lu Dao-Pei Hospital, Beijing, China[2]Shenzhen Geno-immune Medical Institute, Shenzhen, China[3]Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL[4]University of Electronic Science and Technology of China, Sichuan, China[5]Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL
This work was supported by research funds from Science and
Technology Planning Technical Research Project of Shenzhen
(KQTD20140630143254906, JSGG20160229170423146,
JCYJ20160229170523065, and JCYJ20170413154349187)
and University of Electronic Science and Technology of China
(ZYGX2016Z009).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
无
最新[2023]版:
大类|1 区医学
小类|2 区血液学
第一作者:
第一作者机构:[1]Beijing Lu Dao-Pei Hospital, Beijing, China
共同第一作者:
通讯作者:
通讯机构:[2]Shenzhen Geno-immune Medical Institute, Shenzhen, China[4]University of Electronic Science and Technology of China, Sichuan, China[5]Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL[*1]Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, 1200 Newell Dr, ARB R1-252, Gainesville, FL 32610- 0266
推荐引用方式(GB/T 7714):
Jian-Ping Zhang,Rui Zhang,Shih-Ting Tsao,et al.Sequential allogeneic and autologous CAR-T-cell therapy to treat an immune-compromised leukemic patient.[J].Blood advances.2018,2(14):1691-1695.doi:10.1182/bloodadvances.2018017004.
APA:
Jian-Ping Zhang,Rui Zhang,Shih-Ting Tsao,Yu-Chen Liu,Xiaochuan Chen...&Lung-Ji Chang.(2018).Sequential allogeneic and autologous CAR-T-cell therapy to treat an immune-compromised leukemic patient..Blood advances,2,(14)
MLA:
Jian-Ping Zhang,et al."Sequential allogeneic and autologous CAR-T-cell therapy to treat an immune-compromised leukemic patient.".Blood advances 2..14(2018):1691-1695